Partner Headlines - TEVA

  1. Mylan

    IBD
  2. Global Worries Sink U.S. Stocks; Apple Breaches Support Level

    IBD
  3. Teva Getting Serious About Mylan Bid, Says Report

    IBD
  4. 8 IBD 50 Stocks Bucking The Market Sell-Off

    IBD
  5. Mylan: There's No Logic In The Teva Merger Rumor

    Benzinga
  6. Stocks Bleed Some More; Nasdaq Breaches Support Level

    IBD
  7. Mylan Scores Final Win In Patent Challenge On Inhalation Drug

    Benzinga
  8. Momenta, Novartis get FDA OK

    IBD
  9. Momenta, Novartis Win FDA Nod For Generic Copaxone

    IBD
  10. Insys Therapeutics Q4 beats

    IBD
  11. Insys Therapeutics Q4 Beat Drives Short-Lived Rally

    IBD
  12. Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic ...

    Benzinga
  13. Stocks Hitting 52-Week Highs

    Benzinga
  14. Morning Market Gainers

    Benzinga
  15. Three Reasons To Let Akorn Fall Into Your Portfolio

    IBD
  16. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  17. Stocks Rise In Weak Trade; LinkedIn Jumps After Hours

    IBD
  18. Stocks Close Near Session Highs, But Volume Softens

    IBD
  19. Opko Health And Teva Pharmaceutical Industries Surge Following ...

    Benzinga
  20. Analysts are Bullish on IntelliPharmaceuticals Following Deal ...

    GuruFocus
  21. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  22. Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's ...

    Benzinga
  23. Benzinga's Weekend M&A Chatter

    Benzinga
  24. Teva Pharmaceutical

    IBD
  25. Sterne Agee Analyst: Court Win To Boost Net At Teva Pharmaceutical

    Benzinga
  26. Jefferies Weighs In On Specialty Pharmaceuticals After Management ...

    Benzinga
  27. US Stock Futures Slip Ahead Of Home Price, Consumer Confidence ...

    Benzinga
  28. OncoGenex to Regain Rights to Custirsen from Teva

    Benzinga
  29. United Therapeutics: Will It Pass Peers In 2015?

    IBD
  30. Teva Upgraded On Strength Of Copaxone MS Drug

    IBD
  31. UPDATE: Sterne Agee Upgrades Teva Pharmaceutical

    Benzinga
  32. Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic ...

    Benzinga
  33. Merck-Cubist Deal Going Ahead Despite Patent Setback

    IBD
  34. Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI

    GuruFocus
  35. Why Opko Health Is a Better Investment Than Apple

    GuruFocus
  36. Benzinga's M&A Chatter for Tuesday November 18, 2014

    Benzinga
  37. Here Are The Top 25 Analysts On Wall Street

    Benzinga
  38. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  39. Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close ...

    Benzinga
  40. Teva ups full-year EPS outlook

    IBD
  41. UPDATE: Teva Posts Stronger-Than-Expected Q3 Profit, Lifts Forecast

    Benzinga
  42. Earnings Scheduled For October 30, 2014

    Benzinga
  43. Lannett Co. Gets Growth Rx In Generic Drugs Group

    IBD
  44. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD
  45. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  46. Drugmaker M&A Goes On, With Or Without Tax Inversions

    IBD
  47. Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene

    IBD
  48. Teva Reports Results of Strategic Review, Sees 14 Pipeline Projects ...

    Benzinga
  49. Fast Money Halftime Report Final Trade From October 2 - Twitter ...

    Benzinga
  50. Insys Therapeutics Up On Bullish Analyst Initiation

    IBD
  51. Teva Announces UK High Court Gives Positive Judgment In The Company's ...

    Benzinga
  52. 4 Biotechs That Might Be Bought Soon

    IBD
  53. Notable Hedge Funds Disclose Additions And Reductions To Holdings

    Benzinga
  54. Jana Partners LLC Files its 13F

    Benzinga
  55. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  56. Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats

    IBD
  57. Did George Soros Sell His Stake In Israeli Based SodaStream Due ...

    Benzinga
  58. 5 Drug Companies Profiting From Generics

    Benzinga
  59. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  60. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  61. George Soros Reveals His Largest Stake

    GuruFocus
  62. Sofinnova Ventures Closes $500M Fund

    FoxBusiness
  63. Israel's Market Appears Unfazed By Rising Conflict

    IBD
  64. George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps ...

    GuruFocus
  65. UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

    Benzinga
  66. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  67. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  68. Top 4 Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  69. Diamond Hill Capital Comments on Teva Pharmaceutical Industries ...

    GuruFocus
  70. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  71. Teva Pharmaceutical

    IBD
  72. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  73. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  74. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  75. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  76. Teva to buy Labrys Biologics

    IBD
  77. Chicago sues painkiller firms

    IBD
  78. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  79. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  80. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  81. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  82. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  83. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  84. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries ...

    Benzinga
  85. Teva EPS tops; rivals seen?

    IBD
  86. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  87. Earnings Scheduled For May 1, 2014

    Benzinga
  88. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  89. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  90. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  91. Morning Market Losers

    Benzinga
  92. Benzinga's Top #PreMarket Losers

    Benzinga
  93. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase ...

    Benzinga
  94. Nasdaq Could Be in for a Bounce

    FoxBusiness
  95. Actavis got a Pfizer

    IBD
  96. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received ...

    Benzinga
  97. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  98. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  99. Teva Announces First Approval and Launch of Generic Lovaza® Capsules ...

    Benzinga
  100. Market Wrap For April 7: Bears In Complete Control As Markets ...

    Benzinga
Trading Center